MASSIVE Gains: Pelosi’s Biotech Trades Under Scrutiny

London,,Uk,,October,14,,2024:,Former,Speaker,Nancy,Pelosi

President Trump’s explosive accusations against Nancy Pelosi for alleged insider trading have ignited a firestorm as evidence mounts that her husband’s 2024 portfolio crushed Wall Street professionals with suspicious 54% returns.

Story Highlights

Paul Pelosi’s 2024 trades returned 54% versus S&P 500’s 25%, outperforming most hedge funds
Trump accused Pelosis of using “inside information” and called Nancy a “disgusting degenerate”
Senate committee advanced the PELOSI Act in July 2025 to ban congressional stock trading
Key biotech trades doubled in value shortly after purchase, raising timing questions

Trump Escalates Attack on Pelosi Trading Empire

In August 2025, former President Donald Trump publicly accused former House Speaker Nancy Pelosi and her husband Paul of using insider congressional knowledge to achieve unusually high market returns. In a Truth Social post, Trump used derogatory language toward Pelosi and called for investigations into trading practices that he alleged outperformed every major hedge fund in 2024. The accusations center on Paul Pelosi’s documented 54% portfolio return, more than double the S&P 500’s 25% gain during the same period.

Suspicious Trading Patterns Raise Red Flags

Data from congressional trading trackers indicate that some of Paul Pelosi’s trades occurred close in time to legislative developments and market movements. His January 2024 purchase of biotech stocks, particularly in AI-driven medical companies, generated massive gains when those holdings more than doubled within weeks. The performance has drawn scrutiny from Capitol Trades and Quiver Quantitative, platforms that monitor congressional trading disclosures and highlight potential conflicts of interest.

PELOSI Act Gains Legislative Momentum

Senator Josh Hawley’s PELOSI Act cleared a crucial Senate committee hurdle in late July 2025, capitalizing on growing outrage over congressional trading advantages. The legislation would prohibit members of Congress and their spouses from trading individual securities, forcing them into blind trusts or broad market funds. Senator Josh Hawley has alleged that the Pelosis have accumulated “hundreds of millions” through access to nonpublic information, claiming such wealth would be unattainable on congressional salaries alone.

Constitutional Concerns Over Government Overreach

Critics such as financial watchdog groups and ethics reform advocates, including Business Insider and contributors to The Guardian, argue this case raises broader concerns about equal justice and the integrity of U.S. markets. When congressional leaders exploit their privileged positions to enrich themselves while ordinary Americans struggle with inflation and economic uncertainty, it undermines the constitutional framework our founders established. The disclosure requirements currently in place have proven inadequate to prevent abuse, as third-party trackers consistently document suspicious timing and outsized returns that defy market logic.

Trump Accuses Pelosi of Insider Trading After Beating ‘Every Hedge Fund‘ https://t.co/a9SlYLBCRr via @BreitbartNews

— lucky jackson (@lucky1969007) August 10, 2025

Advocacy groups and campaigners for congressional ethics reform, including organizations like Sunlight Foundation and Campaign Legal Center, say they face challenges in combatting what they describe as a culture of personal financial gain among some officeholders. The PELOSI Act represents a critical test of whether Congress will police itself or continue enabling the corruption that erodes public trust in our institutions.